Evolus Enters into Licensing Agreement with Symatese to Excl

Exclusive Distributor Agreement with Symatese Broadens Evolus’ Dermal Filler Footprint Beyond the U.S. to Include the United Kingdom and EuropeEuropean Regulatory Approvals Anticipated in Second Half of 2024Company Continues to Expect to be Fully Funded to Profitability1NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus...

Related Keywords

France , United Kingdom , French , David Moatazedi , Ned Mitchell , Laurent Brones , Eric Perouse , Janet Kettels , International Society Of Aesthetic Plastic Surgery , Linkedin , Communications Consultant , Xpreshan Technology , Exchange Commission , Evolus Inc , Nasdaq , Company Continues To , Evolus International , Daewoong Pharmaceutical Co Ltd , Exclusive Distributor Agreement , Regulatory Approvals Anticipated , Second Half , Fully Funded , Chief Executive Officer , Private Securities Litigation Reform Act , Medytox Settlement Agreements , Annual Report , Quarterly Report , Medical Insights Dermal Filler Market Study , Aesthetic Injectables , Market Insights , International Society , Aesthetic Plastic Surgery International Survey , Global Media Inquiries , Media Inquiries ,